PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients (Q39036924)

8 September 2017

PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients (English)

1 reference

8 September 2017

Julia Y S Tsang

1

1 reference

8 September 2017

Wai-Ling Au

2

1 reference

8 September 2017

Kwan-Yin Lo

3

1 reference

8 September 2017

Yun-Bi Ni

4

1 reference

8 September 2017

Thazin Hlaing

5

1 reference

8 September 2017

Jintao Hu

6

1 reference

8 September 2017

Siu-Ki Chan

7

1 reference

8 September 2017

Kui-Fat Chan

8

1 reference

8 September 2017

Sai-Yin Cheung

9

1 reference

8 September 2017

Gary M Tse

10

1 reference

8 September 2017

language of work or name

English

0 references

publication date

5 January 2017

1 reference

Breast Cancer Research and Treatment

8 September 2017

1 reference

8 September 2017

162

1 reference

8 September 2017

1

1 reference

8 September 2017

19-30

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-016-4095-2

8 September 2017

0 references

cites work

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Prognostic significance of PD-L1 and PD-L2 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Prognostic and predictive value of PDL1 expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

PD-L1 expression in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4095-2

10.1007/S10549-016-4095-2

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference